Navigation Links
Quanterix Announces New Technology Evaluation Agreement
Date:2/22/2011

CAMBRIDGE, Mass., Feb. 22, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix's SiMoA platform technology for diagnostic use.  The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target.

"We are excited to initiate this technology evaluation with Novartis, one of the world's leading healthcare companies," said David Okrongly, Ph.D., Quanterix President and Chief Executive Officer.  "This partnership is an important milestone for Quanterix, and another step toward our goal to be the recognized global leader in sensitive and precise detection technology.  Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology.  SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring.  Automated systems based on SiMoA are being designed to provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cam
'/>"/>

SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
2. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
3. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
6. Sensus Healthcare Announces the Formation of a Medical Advisory Board
7. Sigma-Aldrich Announces Organizational Changes
8. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
9. MiMedx Announces Launch of AmnioFix™
10. Savient Pharmaceuticals Announces Executive Appointments
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... , ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin ... has been accepted by AOAC International as Official First Action method. The AOAC ... by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... a selective thyroid hormone receptor beta agonist, reduced levels ... ... Mich., Jan. 29 QuatRx Pharmaceuticals, a,privately-held biopharmaceutical company developing ... today,announced results from two Phase 1 clinical studies with its ...
... end; no equity financings expected in 2008, - ... in,2008; latest data for all programs to be presented ... of research and development investment in pharmacological, chaperone ... CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
... - Viventia Biotech Inc., a privately held,biopharmaceutical ... focused on cancer, announced today it intends ... realize value from its,pipeline of therapeutic antibodies, ... capabilities. The Company will consider potential,strategic opportunities ...
Cached Biology Technology:Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels 2Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 2Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 3Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 4Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 5Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 6
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... February 21, 2013 A new study published in ... Pathology suggests that cortical type 2 cannabinoid (CB2) ... ischemia. Researchers found that the cannabinoid trans-caryophyllene ... in both in vivo and in vitro animal models. ...
... Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology at ... a new mutation in a gene that causes Schnyder corneal ... vitamin K metabolism suggesting the possibility that vitamin K may ... published in the February 2013 issue of the peer-reviewed journal, ...
... The Entomological Society of America (ESA) and the ... new partnership that will provide ESA members with an ... The ESA is the largest organization ... of entomologists and individuals in related disciplines. Founded ...
Cached Biology News:Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury 2Research discovers gene mutation causing rare eye disease 2Entomological Society of America launches science policy program 2
... to reward the animal for foraging behavior.The Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ... records them, but also allows video replay of ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 1-year license ... NFP/Academic accounts ,one CD-ROM containing ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
Biology Products: